Literature DB >> 21241420

Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa.

Y Briers1, M Walmagh, R Lavigne.   

Abstract

AIMS: To select and evaluate an appropriate outer membrane (OM) permeabilizer to use in combination with the highly muralytic bacteriophage endolysin EL188 to inactivate (multi-resistant) Pseudomonas aeruginosa. METHODS AND
RESULTS: We tested the combination of endolysin EL188 and several OM permeabilizing compounds on three selected Ps. aeruginosa strains with varying antibiotic resistance. We analysed OM permeabilization using the hydrophobic probe N-phenylnaphtylamine and a recombinant fusion protein of a peptidoglycan binding domain and green fluorescent protein on the one hand and cell lysis assays on the other hand. Antibacterial assays showed that incubation of 10(6) Ps. aeruginosa cells ml(-1) in presence of 10 mmol l(-1) ethylene diamine tetraacetic acid disodium salt dihydrate (EDTA) and 50 μg ml(-1) endolysin EL188 led to a strain-dependent inactivation between 3·01 ± 0·17 and 4·27 ± 0·11 log units in 30 min. Increasing the EL188 concentration to 250 μg ml(-1) further increased the inactivation of the most antibiotic resistant strain Br667 (4·07 ± 0·09 log units).
CONCLUSIONS: Ethylene diamine tetraacetic acid disodium salt dihydrate was selected as the most suitable component to combine with EL188 in order to reduce Ps. aeruginosa with up to 4 log units in a time interval of 30 min. SIGNIFICANCE AND IMPACT OF THE STUDY: This in vitro study demonstrates that the application range of bacteriophage encoded endolysins as 'enzybiotics' must not be limited to gram-positive pathogens.
© 2011 The Authors. Journal of Applied Microbiology © 2011 The Society for Applied Microbiology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21241420     DOI: 10.1111/j.1365-2672.2010.04931.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  41 in total

1.  Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa.

Authors:  Yves Briers; Maarten Walmagh; Barbara Grymonprez; Manfred Biebl; Jean-Paul Pirnay; Valerie Defraine; Jan Michiels; William Cenens; Abram Aertsen; Stefan Miller; Rob Lavigne
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

2.  Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.

Authors:  Erin E Gill; Octavio L Franco; Robert E W Hancock
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

Review 3.  Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance.

Authors:  Lucía Fernández; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 4.  Genetically Engineered Phages: a Review of Advances over the Last Decade.

Authors:  Diana P Pires; Sara Cleto; Sanna Sillankorva; Joana Azeredo; Timothy K Lu
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-01       Impact factor: 11.056

Review 5.  Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Authors:  Neelam Taneja; Harsimran Kaur
Journal:  Microbiol Insights       Date:  2016-03-20

6.  Improving the lethal effect of cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module.

Authors:  Roberto Díez-Martínez; Héctor D de Paz; Héctor de Paz; Noemí Bustamante; Ernesto García; Margarita Menéndez; Pedro García
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

7.  The zeamine antibiotics affect the integrity of bacterial membranes.

Authors:  Joleen Masschelein; Charlien Clauwers; Karen Stalmans; Koen Nuyts; Wim De Borggraeve; Yves Briers; Abram Aertsen; Chris W Michiels; Rob Lavigne
Journal:  Appl Environ Microbiol       Date:  2014-12-01       Impact factor: 4.792

Review 8.  Bacteriophage endolysins as novel antimicrobials.

Authors:  Mathias Schmelcher; David M Donovan; Martin J Loessner
Journal:  Future Microbiol       Date:  2012-10       Impact factor: 3.165

Review 9.  Antimicrobial bacteriophage-derived proteins and therapeutic applications.

Authors:  Dwayne R Roach; David M Donovan
Journal:  Bacteriophage       Date:  2015-06-23

10.  DUF3380 Domain from a Salmonella Phage Endolysin Shows Potent N-Acetylmuramidase Activity.

Authors:  Lorena Rodríguez-Rubio; Hans Gerstmans; Simon Thorpe; Stéphane Mesnage; Rob Lavigne; Yves Briers
Journal:  Appl Environ Microbiol       Date:  2016-07-29       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.